According to data collected from
various sources and compiled by Coherent Market Insights, Europe have the
highest annual rate of incidence worldwide, followed by North America and the
lowest in Asia and Middle East.
However, North America holds the
largest share in the global Ulcerative
Colitis Market due to continuous improvements in drugs, increased uptake of
medicines, awareness about treatment and increasing clinical research. APAC
region will show high growth in ulcerative colitis market during forecast years
(2017-2024), due to raising awareness about the treatment, changing lifestyle
will cause to increase prevalence and incidence rate, entry of new drugs in the
market also some companies losing their patent of ulcerative drugs in coming
years, like Humira (adalimumab) lost its patent in 2016 and Remicade will lose
its patent in 2018. Also, some drugs companies have launched their biosimilar
drugs in ulcerative colitis industry. For example, in 2016, India-based Torrent
Pharmaceuticals launched a biosimilar drug under the brand name Adfra to
compete Humira. Humira is a trade name for adalimumab medication owned by
AbbVie Inc.
Some major companies playing
leading role in ulcerative colitis market are AbbVie Inc., Hospira, Celltrion
Healthcare, Johnson and Johnson, F. Hoffmann-La Roche AG, Warner Chilcott,
Janssen Pharmaceuticals Inc. and Takeda Pharmaceuticals Company Ltd.
Ulcerative colitis is the most
common type of inflammatory bowel disease that affects the colon (lining of the
large intestine) and rectum. The inflammation produces tiny sores called
ulcers. These disease can affect people of any age, though prevalence is
especially high among people under 30 years of age. The major symptoms of this
disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other
indications are sudden and unexplained weight loss, loss of appetite, joint
pain, eye disease, thickening of the intestinal wall, blood infection (sepsis),
kidney stones and liver disease. The diagnosis of this disease can be carried
out by physical examination using tests such as colonoscopy, endoscopy, biopsy,
CT scan and blood test.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/238
If ulcerative colitis persists
for over 8 years or longer, it may lead to colon cancer. The people having mild
symptoms of this disease can be cured by over the counter drugs such as Imodium
therapy. However, transcription medicine such as steroid medicines and amino
salicylates are widely used to treat the condition. In severe cases, the patient
may need to undergo surgery to remove the colon, which also helps prevent colon
cancer.
Also, some genetically engineered
drugs also used to treat ulcerative colitis. These drugs are made up of certain
living organisms that help suppress the inflammation, by targeting the
inflammatory proteins such as cytokines. Some genetically engineered drugs
approved by the U.S. FDA for treatment of the condition are Adalimumab
(Humira), Golimumab (Simponi), Infliximab (Remicade) and Vedolizumab (Entyvio).
These genetically engineered
drugs may show some side effects such as fever, headache, hives, low blood
pressure, breathing difficulties, back pain, and stomach pain. Also, these
drugs may affect the immunity power of body to fight infection.
The exact cause for ulcerative
colitis is unknown, though possible reasons are may be genetic factors,
environmental changes, or weakened immune system. The ulcerative colitis can be
prevented by simple healthy habits such as eating small meals throughout the
day, staying well hydrated throughout the day, avoiding fatty foods, and limiting
intake of high-fiber food.
According to data released by the
Centers for Disease Control and Prevention (CDC), there are around 2.2 to 14.3
cases found per 100,000 population per year. Also, according to a study
conducted in 2014 by Crohn’s & Colitis Foundation of America (CCFA),
907,000 people suffered from ulcerative colitis in the U.S. (data based on the
research conducted in between 2011-2014 by CCFA)
High prevalence in developed
regions and increasing incidence rate in emerging economies will play major
role in driving growth of the ulcerative colitis market
According to the study of CCFA,
industrialized countries have highest incidence rate for ulcerative colitis.
This disease is most prevalent in urban areas than in rural areas, also it can
affect to any age group of people but most cases diagnosed are of the age in
between 15 to 35. According the stats of World Gastroenterology Organization
(WGO), there is rising incidence rate in emerging economies such as India. Due
to changing diet and lifestyle pattern, the emerging economies will show high
growth rate in incidence rate of ulcerative colitis in the near future.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/ulcerative-colitis-market-238
Some leading drugs are used to
reduce inflammation and swelling and to cure ulcerative colitis are include
Sulfasalazine (Azulfidine), Mesalamine (Asacol and Lialda), Balsalazide
(Colazal), and Olsalazine (Dipentum), Inflectra, Remsima, Adalimumab (Humira),
and Infliximab (Remicade).
Key Developments
Key players in the market are
focused on various growth strategies such research and development of novel
products, in order to enhance their product portfolio. For instance, in October
2018, Pfizer, Inc.’s Xeljanz, an oral Janus kinase inhibitor showed effectiveness
and safety in the treatment of ulcerative colitis in a 24-month open label
extension study.
Major companies in the market are
involved in various business strategies such research and development of novel
products, in order to enhance their product portfolio. For instance, in March
2019, The Janssen Pharmaceutical Companies of Johnson & Johnson announced
the Phase III data UNFI study data for Stelara, a subcutaneous maintenance
therapy, which showed positive results as maintenance therapy in adults
suffering from moderate to severe ulcerative colitis.
Major companies in the market are
involved in various growth strategies such research and development of novel
products, in order to enhance their market presence. For instance, in August
2019, Takeda Pharmaceutical Company Limited, submitted new drug application
(NDA) to Ministry of Health, Labour and Welfare in Japan for subcutaneous
formulation of vedolizumab, which will be used as maintenance therapy in adults
with moderate to severe ulcerative colitis.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/238
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment